

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. : 7,541,033
Issued: : June 2, 2009
First Applicant : DICKINSON, Craig Duane
Serial No. : 10/542,508
International Application Date : January 21, 2004
National Entry Date: July 15, 2005
Entitled : HUMANIZED ANTI-IL-18 ANTIBODIES
Docket No. : X-15950

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 C.F.R. 1.323

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The patentees of the above-identified patent respectfully request that you issue a Certificate of Correction to correct certain errors in the patent.

Some of the errors are typographical and were made inadvertently. The remaining errors occurred during the printing of the patent.

Please charge any fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Respectfully submitted,

/Andrea M. Castetter/
Andrea M. Castetter
Agent for Applicantss
Registration No. 63,964
Phone: 317-433-0895

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

June 11, 2010

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,541,033
APPLICATION NO.: 10/542,508
DATED : June 2, 2009
INVENTOR(S) : Craig Duane Dickinson et al

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

The priority is not correctly reflected on the face of the patent.

Insert on Front Page of patent:

Related U.S. Application Data
Provisional application No. 60/442,798 filed on Jan. 24, 2003

Insert on page 1 of specification located underneath the title:

This is a national phase application, under 35 USC 371, for PCT/US04/000119, filed 21 January 2004, which claims the benefit, under 34 USC 119(e), of US provisional application 60/442,798, filed on 24 January 2003.

MAILING ADDRESS OF SENDER:

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288